Amarin Corp Plc (AMRN)

[HDGabor]

i-

I did not say that pancreatitis could not be measured, but the APPROACH study wasn't an event-driven study, the Primary Outcome Measures was "Efficacy of ISIS-APOCIIIRx as measured by the percent change in fasting triglycerides from baseline".

Best,
G

ps.: I could not find more details other than "APPROACH is a randomized, double-blind, placebo-controlled, 52-week Phase 3 study in 66 patients with FCS, a rare disease affecting approximately 3,000 to 5,000 patients worldwide ... Volanesorsen-treated patients with the highest documented frequency of pancreatitis attacks suffered no attacks during the 52-week treatment period (p=0.02)" ... zero pancreatitis in the treatment arm and ??? pancreatitis in the placebo arm